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Antithrombin (AT) is known as an important physiological anticoagulant. AT inactivates thrombin and multiple
other coagulation factors, thereby strongly inhibiting the over-activation of the coagulation system during
disseminated vascular coagulation (DIC). AT also suppresses the pro-inflammatory reactions that are promoted
through protease-activated receptor-1 during sepsis. One of the unique characteristics of AT is the conformational
change it undergoes when binding to heparin-like molecules. The anticoagulant function is greatly accelerated after
AT binds to externally administered heparin in the circulating blood. Meanwhile, AT also binds to syndecan-4 on the
cell surface under physiological conditions, thereby contributing to local antithrombogenicity. The binding of AT
and syndecan-4 upregulates prostaglandin I2 production, downregulates pro-inflammatory cytokine production, and
suppresses the leukocyte-endothelial interaction. Other than these activities, recent preclinical studies have reported
that AT might inhibit neutrophil necrotic cell death and the ejection of neutrophil extracellular traps. Together, these
effects may lead to the attenuation of inflammation by decreasing the level of damage-associated molecular patterns.
Although a number of animal studies have demonstrated a survival benefit of AT, the clinical benefit has long been
argued since the effect of high-dose AT was denied in 2001 in a large-scale randomized controlled trial targeting
patients with severe sepsis. However, recent clinical studies examining the effects of a supplemental dose of AT in
patients with sepsis-associated DIC have revealed that AT is potentially effective for DIC resolution and survival
improvement without increasing the risk of bleeding. Since DIC is still a major threat during sepsis, the optimal
method of identifying this promising drug needs to be identified.
Keywords: Antithrombin, Sepsis, Disseminated intravascular coagulation, Thrombin, Neutrophil extracellular traps,
Damage-associated molecular pattern, Necrosis, Syndecan-4, Heparin, Protease-activated receptorIntroduction
As was written in a recent review by Hunt [1], the fun-
damental strategy for caring for patients with sepsis-
associated disseminated intravascular coagulation (DIC)
is the management of underlying infection. During sep-
tic DIC, thrombus formation is driven by activated co-
agulation, the impairment of anticoagulant mechanisms
including the antithrombin (AT) system, and compro-
mised fibrin removal arising from the depression of the
fibrinolytic system [2]. Microvascular thrombosis con-
tributes to diminished oxygen delivery and subsequent* Correspondence: toshiiba@cf6.so-net.ne.jp
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unless otherwise stated.organ dysfunction. Accordingly, anticoagulant therapy is
expected to play some role in alleviating this dangerous
condition [3]. In the early 2000s, some large-scale ran-
domized controlled trials (RCTs) targeting severe sepsis
were conducted [4-6], but none of the anticoagulants
that were examined are currently available for clinical
use. Actually, sepsis-associated DIC, instead of severe
sepsis, might be an appropriate target for these anticoagu-
lant therapies. Indeed, some subgroup analyses of subjects
with sepsis-associated DIC in the above-mentioned RCTs
have revealed effects on mortality [7,8]. However, the
effects of these anticoagulants on septic DIC have not
been examined in the well-qualified studies. Recently, a
small-sized but properly designed RCT succeeded in dem-
onstrating the efficacy of a physiological dose of AT for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a nationwide administrative database in Japan revealed a
positive effect of physiological AT use on mortality. Under
these circumstances, the ? Harmonized guidance for DIC?
has been released by the International Society on Throm-
bosis and Haemostasis (ISTH) [10]. In this guidance, AT is
graded as ? potentially recommended? . Therefore, our
present and future tasks will be to search for appropriate
measures for AT use and to accumulate sufficient evidence.
Review
Preclinical evaluation
AT is a vitamin K-independent glycoprotein with a molecu-
lar weight of approximately 59 kDa and is one of the major
natural anticoagulants that have been aggressively studied
[8,11,12]. AT inhibits thrombin in a 1:1 fashion and leads to
the formation of a thrombin-antithrombin complex (TAT),
thereby inactivating the enzymatic activity of thrombin and
leading to its elimination from the circulation. Therefore, the
inactivation of thrombin is considered to be a rational thera-
peutic strategy for DIC. Apart from anticoagulation, the anti-
inflammatory function of AT can also be explained by the
neutralization of thrombin. Thrombin has been implicated
in the inflammatory cascade [13]; specifically, it increases
leukocyte rolling and adhesion [14] by increasing the expres-
sion of endothelial P- and E-selectin [15,16] and intercellular
adhesion molecule-1 (ICAM-1) [16], thereby promoting
leukocyte recruitment. Thrombin also elicits an inflamma-
tory reaction through its receptor, protease activated receptor
(PAR)-1, on the cell surface [17]. PAR-1 is known to play piv-
otal roles in the activation of inflammation [18] by inducing
the production of pro-inflammatory cytokines and chemo-
kines by the endothelium [16,19]. Thus, the anti-
inflammatory function of AT is thought to depend, at
least in part, on the blockage of the effects of PAR-1.
Another cell-modulating activity of AT is induced after
binding with its specific receptor syndecan-4, a type of
heparin-like glycosaminoglycan (GAG), on various types
of cell surfaces [20]. One major property of AT is thought
to be its ability to stimulate prostacyclin production by
endothelial cells through the binding of AT and syndecan-
4 [21]. Prostacyclin exerts an anti-inflammatory function
by blocking neutrophil tethering on the vascular endothe-
lium [22] and by downregulating the production of pro-
inflammatory cytokines [23]. When AT and syndecan-4
bind together on neutrophils, monocytes, and lympho-
cytes, their interactions with the endothelium are sup-
pressed. The downregulation of P-selectin may also be
involved in the vessel wall integrity-preserving properties
of AT [24].
The balance between the anticoagulation effect and the
anti-inflammatory cellular function is dominantly regulated
by heparins. AT contains a heparin-binding domain, and
its anticoagulation activity is maximized by several ordersof magnitude after binding with heparin in the blood-
stream (Figure 1). This binding of heparin to the lysyl side
chains of AT induces a nonreversible conformational
change leading to a high affinity towards thrombin. Since
the latter effect is more desired in sepsis, the coadminis-
tration of AT and heparin might not be a good choice for
the treatment of patients with sepsis and not associated
with DIC [7].
Recently, the mechanisms involved in the pathological
derangement of coagulation in patients with sepsis have
become increasingly clear. Tissue factor (TF) is a key
factor in thrombin generation during sepsis [25]. However,
recent studies have elucidated that damage-associated mo-
lecular patterns (DAMPs) from necrotic cells and neutro-
phil extracellular traps (NETs) and their components also
play major roles in the activation of the coagulation sys-
tem [26,27]. NETs activate coagulation by expressing tis-
sue factor [28] and stimulate platelets via histones [29],
which are also strong promoters of the extrinsic pathway
[30]. Interestingly, recent studies have reported that anti-
thrombin suppresses necrotic cell death and NET forma-
tion in the animal and in vitro studies [31,32].
In animal models, the effect of AT substitution on sur-
vival was first reported by Triantaphyllopoulos [33] in a
lipopolysaccharide (LPS)-induced rabbit model of sepsis.
Similar effects were reported in an Escherichia coli-in-
duced primate model of sepsis by Taylor et al. [34].
Other than these reports, the protective effect of AT on
mortality has been reported in various models of sepsis
[35,36]. In our rat model, all the rats died when treated
with a continuous infusion of 10.0 mg/kg of LPS over 24 h,
but 50% of the rats survived when treated with low-dose
AT and all the rats survived when treated with high-dose
AT [37]. These results were adopted as the fundamental
basis of the clinical studies.
Clinical evaluation
A pharmacological dose of recombinant activated pro-
tein C [4], high-dose AT [5], and tissue factor pathway
inhibitor [6] are widely known to have failed to demon-
strate a survival benefit among patients with severe
sepsis in large-scale RCTs. Some reasons have been
suggested to explain the failures of these trials. First,
even if the anti-inflammatory effects of anticoagulants
have been advocated in animal and ex vivo studies, anti-
coagulant therapies seem to be effective only in the
septic patients with DIC, but not in those without DIC,
in a clinical setting. Subgroup analyses performed in
subjects with DIC in the KyberSept trial [5] and PROW-
ESS trial [38] revealed improvements in survival [7,8].
The second reason is that ? pharmacological ? or ? high-
dose ? anticoagulants may cause bleeding. For example,
treatment with high-dose AT was correlated with a
































Figure 1 Multifactorial functions of antithrombin in circulating blood and on the cell surface. The interactions between antithrombin (AT)
and the endothelium are shown in the figure. The affinity of antithrombin to thrombin and its enzymatic inhibition are increased by the binding
of the heparin-binding site of AT to syndecan-4 on the cell surface or externally administered heparins. Thrombin loses its coagulant activity after
the formation of a thrombin-antithrombin complex. Other than thrombin, AT inactivates factors Xa and IXa. As for its anti-inflammatory function,
AT inactivates thrombin, thereby attenuating the cellular reactions through the activation of protease-activated receptor (PAR)-1.
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group and 22.0% in the AT-treated group (relative risk
[RR], 1.71 [95% confidence interval [CI], 1.42 ? 2.06]).
Thus, increased bleeding events might diminish the
beneficial effects of AT. Third, the concomitant use of
heparin might interfere with the effect of AT. As a mat-
ter of fact, nearly 70% of high-dose antithrombin-
treated patients received heparin. Hoffmann et al.
[39,40] analyzed the data from KyberSept and reported
increased bleeding risks associated with antithrombin
plus concomitant heparin, compared with antithrombin
alone. Regarding this issue, we will introduce the latest
studies examining the above problems in the following
section.
While a high dose can be harmful, an insufficient dose
will be ineffective. So far, we have conducted two non-
randomized multi-institutional post-marketing surveys
to determine the optimal AT dose. In the first survey, a
total of 729 sepsis-associated DIC patients with an AT
activity of 70% or lower were analyzed. Among these pa-
tients, AT was substituted at a dose of either 1,500 IU/
day (n = 650) or 3,000 IU/day (n = 79) for three consecu-
tive days. The dose selection was made by the attendingphysicians based primarily on each patient's condition,
and the baseline AT activity level was lower among the
patients who received 3,000 IU/day. As a result, the sur-
vival of the patients who had received 1,500 IU/day was
65.2%, while that of the patients who received 3,000 IU/
day was 74.7%, and a logistic regression analysis showed
that the supplemented AT dose of 3,000 IU/day contrib-
uted to a better survival outcome (odds ratio [OR], 1.912;
P = 0.026) [41]. Whether this supplemental dose of AT in-
creased the bleeding risk remained unclear because a pla-
cebo control was not included in this post-marketing
survey. Nevertheless, since the incidence was 6.52% (major
bleeding, 1.71%), which was even lower than that of the
control group (major bleeding, 5.7%) in the KyberSept trial
[5], we believe that AT supplementation for septic DIC pa-
tients is an acceptable treatment.
Since the survival difference did not reach statistical
significance and the effect of AT was more prominent in
severer cases (lower baseline AT activity) in the first sur-
vey, we conducted a second survey in septic DIC patients
with baseline AT activities of less than 40%. A total of 307
patients (259 patients received 1,500 IU/day and 48
patients received 3,000 IU/day) were investigated in this
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higher rate of DIC resolution (66.7% vs. 45.2%, P = 0.007)
and a better survival outcome (77.1% vs. 56.4%, P = 0.010)
among the patients supplemented with 3,000 IU/day of
AT. Bleeding events were observed in 6.96% (major bleed-
ing, 3.04%) of the patients supplemented with 1,500 IU/
day and 6.52% (major bleeding, 4.35%) of the patients sup-
plemented with 3,000 IU/day; this difference was not sig-
nificant [42].
From these results, we assumed that AT supplementa-
tion at a sufficient dose could be expected to demonstrate
a favorable effect. If so, which dose is most likely to be suf-
ficient? The recovered AT activity level may provide a clue
as to the most appropriate dose. The mean AT activity
level in the patients supplemented with 3,000 IU/day re-
covered to within the normal range (>80%), while that of
patients supplemented with 1,500 IU/day never reached
the normal range in either survey in the second survey. In
the first survey, the baseline AT activity was approximately
50%, and it rose up to above 80% in the patients supple-
mented with 1,500 IU/day. So, roughly 1,500 IU/day may
be adequate if the initial AT activity level is above 50%;
however, if the initial AT activity level is less than 50%,
3,000 IU/day will likely be needed. However, the Japanese
health-care system allows the use of 3,000 IU/day of
AT only in limited, severe cases. Thus, combination
therapy with AT and recombinant thrombomodulin is
now attracting attention [43].
Almost simultaneously with the above-mentioned sur-
veys, the Japanese Association for Acute Medicine (JAAM)
performed a multicenter placebo-controlled RCT in 60
septic DIC patients with baseline antithrombin levels of
50%? 80%. The treatment group (30 cases) received a sup-
plemental dose of AT (30 IU/kg/day ? 3 days), and the
mean AT activity recovered to 107.6% ? 24.5% in the treat-
ment group, while it remained around 60% in the placebo
group. The DIC resolution rate was 53.3% (16/30) in the
treatment group, which was more than double that in the
control group (20.0%, 6/30), and a significant improvement
in DIC resolution was observed [9].
Following these reports, Tagami et al. [44] performed
an analysis using a nationwide administrative database in
Japan. A total of 9,075 patients with severe pneumonia
and DIC were categorized into an antithrombin group
(2,663 cases) and a control group (6,412 cases). Propensity
score matching created a matched cohort of 2,194 pairs of
patients with and without antithrombin treatment. The
results demonstrated that standard AT supplementation
(1,500? 3,000 IU/day ? 3 days) was associated with a 9.9%
(95% CI, 3.5% ? 16.3%) reduction in 28-day mortality.
Multiple logistic regression analyses showed an associ-
ation between AT use and the 28-day mortality (adjusted
odds ratio, 0.85 [95% CI, 0.75? 0.97]). Based on the above-
mentioned evidence, a supplemental dose of AT is assumedto be effective in patients with sepsis-associated DIC. How-
ever, to confirm this hypothesis, an adequately powered
RCT will be required.
One topic in anticoagulant therapy is the development
of recombinant AT. Only plasma-derived AT is presently
available in Japan, but the development of recombinant
AT is currently underway. A phase 3 trial has just been
completed, and the results will be published in the near
future.
Usefulness as a biomarker
We have introduced the therapeutic characteristics of
AT. However, AT can also be used as a biomarker for
DIC. A reduced plasma level of AT in patients with DIC
is a well-known fact [45]. Furthermore, decreased AT ac-
tivity is reportedly correlated with the severity and out-
come of patients [46]. Therefore, AT activity has become
a popular test in patients with coagulopathy in Japan.
The mechanisms responsible for the decrease in AT during
sepsis are considered to be as follows: the consumption of
AT during activated coagulation [47], the decreased syn-
thesis of AT in the liver [47,48], the degradation of AT
by neutrophil elastase [49,50], and the leakage of AT
to the extravascular space. The reduced AT activity level
results in a decreased ability to undergo thrombin inacti-
vation, leading to the further acceleration of the coagula-
tion system.
We previously reported that the AT activity level is ap-
proximately 80% of normal in septic patients without
organ dysfunction, decreasing to approximately 60% in pa-
tients with severe sepsis, and 40% in patients with full-
blown DIC [51]. Others have reported that the diagnostic
value of an area under the receiver operating characteristic
curve (AUC) of the AT activity exceeded 0.8 for the pre-
diction of patient outcome [52,53]. Thus, we think that
AT is an excellent discriminator of the severity of sepsis.
Recently, Choi et al. [54] reported a significant correlation
between AT and the DIC score in patients with sepsis,
suggesting that AT is a good indicator of DIC severity. In-
deed, AT had a significant prognostic power in a Kaplan-
Meier analysis, showing a higher hazard ratio than con-
ventional coagulation markers, such as D-dimer. Similar
observations were reported in patients with conditions
other than sepsis, such as multiple trauma or major sur-
gery [45,55].
We conducted a multi-institutional observational study
and analyzed samples from 78 sepsis patients with coagu-
lopathy. Data collection was begun within 48 h after the
platelet count first decreased to less than 150,000/mm3,
and sequential changes in the coagulation markers, includ-
ing ATactivity, protein C activity, fibrin and fibrinogen deg-
radation products (FDP), D-dimer, thrombin-antithrombin
complex, plasmin α2-antiplasmin complex, soluble fibrin,
and total plasminogen activator inhibitor-1, were evaluated.
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lecular markers were associated with the onset of organ
dysfunction beginning at an early stage of sepsis and that
AT activity and protein C activity exhibited the highest
predictive values among these parameters [56]. Yanagida
et al. [57] and Oshiro et al. [58] reported similar results
for trauma patients.
Although the measurement of AT activity is valuable
for estimating the severity and outcome of patients, it
has not been included in major diagnostic criteria since
the measurement of AT activity cannot be performed all
day in many local laboratories [59]. In fact, all the major
scoring systems consist of some of four routine labora-
tory tests: platelet count, prothrombin time (PT), fibrin-
related marker level, and fibrinogen [60,61]. Although
still controversial [62], Egi et al. [63] suggested that the
inclusion of AT activity in the diagnostic criteria may
provide a better diagnostic performance.
The other unique feature of antithrombin activity is
its usefulness as a prognostic indicator after antithrombin
supplementation. We evaluated the efficacy of meas-
uring AT activity in 192 septic DIC patients supple-
mented with AT. A logistic regression analysis indicated
that not only the baseline AT activity level but also
the ΔAT activity level (the AT value on day 3 − the
AT value on day 0) was related to patient outcome. Fur-
thermore, the results revealed that an increase in AT
activity had the largest contribution to patient sur-
vival (Table 1).
In summary, the sensitivity and/or specificity of AT ac-
tivity for predicting the morbidity and mortality of septic
DIC is superior to that of global coagulation tests, and we
recommend that AT activity be included in future diagnos-
tic criteria for septic DIC. We also recommend examining
sequential changes in this marker when supplementa-
tion therapy is performed. The baseline AT value may
also help to determine appropriate candidates for anti-
coagulant therapy [41].Table 1 Relationship between outcome (28-day survival)
and various factors using the stepwise method of logistic
regression analysis
Odds ratio P value 95% confidence interval
Age 0.973 0.060 0.945? 1.001
Body weight 1.032 0.071 0.997? 1.068
Basement AT activity 1.042 0.006 1.012? 1.073
ΔAT activity 1.031 0.001 1.012? 1.050
Baseline fibrinogen 1.002 0.056 1.000? 1.005
ΔSIRS score 0.681 0.008 0.512? 0.906
Respiratory infection 0.490 0.061 0.232? 1.035
Δ value on day 3 − value on day 0, AT antithrombin, SIRS systemic
inflammatory response syndrome (original data).Conclusions
AT, an important natural anticoagulant, inhibits over-
activated coagulation and inflammation during sepsis
through multifactorial pathways. However, its activity
decreases significantly in sepsis-associated DIC. Al-
though high-dose antithrombin administration has failed
to provide a survival benefit, a supplementation dose
that restores AT activity to within a normal range is ex-
pected to be useful. Currently, the ? global guidance for
the diagnosis and treatment of DIC ? rates AT substitu-
tion as ? potentially recommended, ? meaning that AT can
be used but that ? further clinical study is required to
prove its efficacy ? .
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